The current financial score of Zimmer Biomet Holdings Inc is 8.44. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 2.18B, representing a year-over-year increase of 4.80%, while its net profit experienced a year-over-year increase of 29.78%.
The current valuation score of Zimmer Biomet Holdings Inc is 8.63. Its current P/E ratio is 24.66, which is 380.97% below the recent high of 118.60 and 21.58% above the recent low of 19.34.
The current earnings forecast score of Zimmer Biomet Holdings Inc is 6.69. The average price target is 106.87, with a high of 129.34 and a low of 93.00.
The current price momentum score of Zimmer Biomet Holdings Inc is 3.69. Currently, the stock price is trading between the resistance level at 101.66 and the support level at 90.25, making it suitable for range-bound swing trading.
The current institutional shareholding score of Zimmer Biomet Holdings Inc is 10.00. The latest institutional shareholding proportion is 101.82%, representing a quarter-over-quarter decrease of 3.74%. The largest institutional shareholder is Van Duyn Dodge & E. Morris Cox, holding a total of 24.12M shares, representing 1.09% of shares outstanding, with 4.70% decrease in holdings.
The current risk assessment score of Zimmer Biomet Holdings Inc is 7.84. The company's beta value is 0.48. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.